LBA1 **Plenary Session**

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).

Frank A. Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter Peters, Robert J. Behrens, Christopher Hanyoung Lieu, Khalid Matin, Deirdre J. Cohen, Samara L. Potter, Wendy L. Frankel, Ardaman Shergill, Dennis Hsu, Anke C. Reinacher-Schick, Tyler Zemla, Clare A. Gatten, Eileen M. O'Reilly, Jeffrey A. Meyerhardt; Mayo Clinic Rochester, Rochester, MN; Alliance Statistics and Data Management Center and Mayo Clinic Rochester, Rochester, MN; Asklepios Tumorzentrum Hamburg, Hamburg, Germany; Baylor University Medical Center, Dallas, TX; Iowa Wide Oncology Research Coalition, NCORP, Des Moines, IA; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO; VCU Massey Cancer Center, Richmond, VA; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Nationwide Children's Hospital, Columbus, OH; The Ohio State University Wexner Medical Center, Columbus, OH; Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA; St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA

LBA2 **Plenary Session**

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Jean Bourhis, Anne Auperin, Christian Borel, Gautier Lefebvre, Severine Racadot, Lionnel Geoffrois, Xu Shan Sun, Esma Saada, Beatriz Cirauqui, Tomasz Rutkowski, Stephanie Henry, Anouchka Modesto, Alison Johnson, Benoit Calderon, Yoann Pointreau, Elisabeth Perez Ruiz, Joanna Kazmierska, Amanda Psyrri, Ricard Mesia, Yungan Tao, GORTEC; CHUV, Bâtiment Hospitalier, Lausanne, Switzerland; Gustave Roussy, Villejuif, France; Institut de Cancérologie Strasbourg Europe, Strasbourg, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Institut de Cancérologie de Lorraine, Medical Oncology Department, Vandoeuvre-lés-Nancy, France; Hopital Nord Franche Comté, Montbelliard, France; Centre Antoine Lacassagne, Nice, France; Institut Català d'Oncologia Badalona, Barcelona, Spain; Maria Skłodowska-Curie Institute of Oncology, Gliwice, Poland; BGOG & CHU UCL Namur Site Sainte Elisabeth, Namur, Belgium; Claudius Regaud Institute, Toulouse, France; Centre François Baclesse, Caen, France; Institut Sainte Catherine, Avignon, France; Centre Jean Bernard, Le Mans, France; Hospital Regional Universitario de Malaga, Marbella, Spain; Greater Poland Cancer Center, Poznan, Poland; Section of Medical Oncology, Attikon University Hospital, Athens, Greece; Institut Català d'Oncologia-Badalona, B-ARGO group, IGTP, Badalona, Spain

LBA3 **Plenary Session**

Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).

Andrew Tucker Kuykendall, Naveen Pemmaraju, Kristen M. Pettit, Joseph James Shatzel, Alessandro Lucchesi, Valentin García-Gutierrez, Jiří Mayer, Abdulraheem Yacoub, Harinder Gill, Antonin Hlusi, Daniel Sasca, Joseph M. Scandura, Marina Kremyanskaya, Phil Dinh, Sarita Khanna, Suneel K. Gupta, Arturo Molina, Aniket Bankar, on behalf of the VERIFY Investigators; Moffitt Cancer Center, Tampa, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; Oregon Health & Science University, Portland, OR; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy; Hospital Universitario Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain; University Hospital Brno and Masaryk University, Brno, Czech Republic; University of Kansas Cancer Center, Westwood, KS; Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong; Palacky University and University Hospital Olomouc, Olomouc, Czech Republic; Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz, Mainz, Germany; New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY; Mount Sinai Hospital, New York, NY; Protagonist Therapeutics, Inc., Newark, CA; Princess Margaret Cancer Centre, Toronto, ON, Canada

LBA4 **Plenary Session**

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent *ESR1* mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.

Nicholas C. Turner, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia X. Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen K. L. Chia, Peter A. Fasching, Adam Brufsky, Zbigniew Nowecki, Javier Pascual, Lionel Moreau, Shin-Cheh Chen, Sasha McClain, Steven Fox, Cynthia Huang Bartlett, Francois Clement Bidard; Royal Marsden Hospital, London, United Kingdom; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Universitätsklinikum Ulm, Ulm, Germany; Washington University School of Medicine, St. Louis, MO; Weill-Cornell Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, New York, NY; IRCCS Ospedale San Raffaele, Milan, Italy; Winship Cancer Institute, Atlanta, GA; Nagoya City University, Nagoya, Japan; BC Cancer Agency, Vancouver, BC, Canada; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; UMPC Magee-Womens Hospital, Pittsburgh, PA; Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Warsaw, Poland; Hospital Universitario Virgen de la Victoria, Málaga, Spain; Pôle Santé République, Clermont-Ferrand, France; Chang Gung Memorial Hospital Linkou Branch, Taoyuan City, Taiwan; AstraZeneca, Gaithersburg, MD; AstraZeneca, Cambridge, United Kingdom; Institut Curie, St Cloud, France

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2025, issue of the *Journal of Clinical Oncology*.

LBA5 **Plenary Session**

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).

Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg, Kei Muro, Daniela Molena, Eric Van Cutsem, Woo Jin Hyung, Lucjan Wyrwicz, Do-Youn Oh, Takeshi Omori, Markus H. Moehler, Marcelo Garrido, Sulene S.C. Oliveira, Moishe Liberman, Victor Castro Oliden, Elizabeth Catherine Smyth, Olivier Serrano, Eric Heilbron, Alejandra Negro, Josep Tabernero; Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Institute of Clinical Cancer Research, Krankenhaus Nordwest, University Cancer Center, Frankfurt, Germany; Department of Gastrointestinal Medical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Gastroenterology/Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium; Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea; Department of Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan; Research Center for Immunotherapy (FZI), Johannes Gutenberg-University Clinic, Mainz, Germany; Hemato-Oncology Department, SAGA Clinical Trials Centre and Universidad Mayor, Santiago, Chile; Clinical Oncology, The Clinical Research Center, Northern Riograndense League Against Cancer, Natal, Rio Grande Do Norte, Brazil; Division of Thoracic Surgery, Department of Surgery, Centre Hospitalier de l'Université de Montréal, Centre de Recherche du CHUM, Montreal, QC, Canada; National Institute of Neoplastic Diseases (INEN), Lima, Peru; Oxford University Hospitals NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Cytel Inc, AstraZeneca, Paris, France; Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg, MD; Medical Oncology Department, Vall d'Hebron Hospital Campus & Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain